28390852|t|Cardiovascular comorbidity in patients with chronic obstructive pulmonary disease in the Canary Islands (CCECAN study)
28390852|a|Numerous studies have shown a high prevalence of cardiovascular disease in patients with chronic obstructive pulmonary disease (COPD). The aim of this study was to analyse the prevalence of cardiovascular risk factors and comorbidity in a Canary Islands population diagnosed with COPD, and compared it with data from the general population. A cross-sectional study was carried out in 300 patients with COPD and 524 subjects without respiratory disease (control group). The two groups were compared using standard bivariate methods. Logistic regression models were used to estimate the cardiovascular risks in COPD patients compared to control group. Patients with COPD showed a high prevalence of hypertension (72%), dyslipidaemia (73%), obesity (41%), diabetes type 2 (39%), and sleep apnoea syndrome (30%) from mild stages of the disease (GOLD 2009). There was a 22% prevalence of cardiac arrhythmia, 16% of ischaemic heart disease, 16% heart failure, 12% peripheral vascular disease, and 8% cerebrovascular disease. Compared to the control group, patients with COPD had a higher risk of dyslipidaemia (OR 3.24, 95% CI; 2.21-4.75), diabetes type 2 (OR 1.52, 95% CI; 1.01-2,28), and ischaemic heart disease (OR 2.34, 95% CI; 1.22-4.49). In the case of dyslipidaemia, an increased risk was obtained when adjusted for age, gender, and consumption of tobacco (OR 5.04, 95% CI; 2.36-10.74). Patients with COPD resident in the Canary Islands have a high prevalence of hypertension, dyslipidaemia, ischaemic heart disease, and cardiac arrhythmia. Compared to general population, patients with COPD have a significant increase in the risk of dyslipidaemia.
28390852	0	14	Cardiovascular	T029	C3887460
28390852	15	26	comorbidity	T078	C0009488
28390852	30	38	patients	T101	C0030705
28390852	44	81	chronic obstructive pulmonary disease	T047	C0024117
28390852	89	103	Canary Islands	T083	C0454662
28390852	105	117	CCECAN study	T062	C0008972
28390852	128	135	studies	T059	C0947630
28390852	149	164	high prevalence	T081	C1512456
28390852	168	190	cardiovascular disease	T047	C0007222
28390852	194	202	patients	T101	C0030705
28390852	208	245	chronic obstructive pulmonary disease	T047	C0024117
28390852	247	251	COPD	T047	C0024117
28390852	258	261	aim	T078	C1947946
28390852	270	275	study	T062	C0008972
28390852	283	305	analyse the prevalence	T081	C0033106
28390852	309	336	cardiovascular risk factors	T047	C0850624
28390852	341	352	comorbidity	T078	C0009488
28390852	358	372	Canary Islands	T083	C0454662
28390852	373	383	population	T081	C0032659
28390852	384	393	diagnosed	T033	C0011900
28390852	399	403	COPD	T047	C0024117
28390852	426	430	data	T078	C1511726
28390852	440	458	general population	T098	C0683971
28390852	462	483	cross-sectional study	T062	C0010362
28390852	507	515	patients	T101	C0030705
28390852	521	525	COPD	T047	C0024117
28390852	534	542	subjects	T098	C0080105
28390852	551	570	respiratory disease	T047	C0035242
28390852	572	585	control group	T096	C0009932
28390852	596	602	groups	T098	C1257890
28390852	608	616	compared	T052	C1707455
28390852	623	649	standard bivariate methods	UnknownType	C0681927
28390852	651	677	Logistic regression models	T062	C0871424
28390852	691	699	estimate	T081	C0750572
28390852	704	724	cardiovascular risks	T047	C0850624
28390852	728	732	COPD	T047	C0024117
28390852	733	741	patients	T101	C0030705
28390852	754	767	control group	T096	C0009932
28390852	769	777	Patients	T101	C0030705
28390852	783	787	COPD	T047	C0024117
28390852	797	812	high prevalence	T081	C1512456
28390852	816	828	hypertension	T047	C0020538
28390852	836	849	dyslipidaemia	T047	C0242339
28390852	857	864	obesity	T047	C0028754
28390852	872	887	diabetes type 2	T047	C0011860
28390852	899	920	sleep apnoea syndrome	T047	C0037315
28390852	937	958	stages of the disease	T060	C0699749
28390852	988	998	prevalence	T081	C0033105
28390852	1002	1020	cardiac arrhythmia	T033	C0003811
28390852	1029	1052	ischaemic heart disease	T047	C0010068
28390852	1058	1071	heart failure	T047	C0018801
28390852	1077	1104	peripheral vascular disease	T047	C0085096
28390852	1113	1136	cerebrovascular disease	T047	C0007820
28390852	1154	1167	control group	T096	C0009932
28390852	1169	1177	patients	T101	C0030705
28390852	1183	1187	COPD	T047	C0024117
28390852	1194	1205	higher risk	T033	C3843761
28390852	1209	1222	dyslipidaemia	T047	C0242339
28390852	1253	1268	diabetes type 2	T047	C0011860
28390852	1303	1326	ischaemic heart disease	T047	C0010068
28390852	1372	1385	dyslipidaemia	T047	C0242339
28390852	1390	1404	increased risk	T033	C3843761
28390852	1423	1431	adjusted	T169	C0456081
28390852	1436	1439	age	T032	C0001779
28390852	1441	1447	gender	T032	C0079399
28390852	1453	1475	consumption of tobacco	T055	C0543414
28390852	1507	1515	Patients	T101	C0030705
28390852	1521	1525	COPD	T047	C0024117
28390852	1526	1534	resident	T098	C2347958
28390852	1542	1556	Canary Islands	T083	C0454662
28390852	1564	1579	high prevalence	T081	C1512456
28390852	1583	1595	hypertension	T047	C0020538
28390852	1597	1610	dyslipidaemia	T047	C0242339
28390852	1612	1635	ischaemic heart disease	T047	C0010068
28390852	1641	1659	cardiac arrhythmia	T033	C0003811
28390852	1661	1669	Compared	T052	C1707455
28390852	1673	1691	general population	T098	C0683971
28390852	1693	1701	patients	T101	C0030705
28390852	1707	1711	COPD	T047	C0024117
28390852	1719	1730	significant	T081	C0237881
28390852	1731	1751	increase in the risk	T033	C3843761
28390852	1755	1768	dyslipidaemia	T047	C0242339